News2016-12-08T23:51:25+01:00
1412, 2017

La EMA (Agencia Europea del Medicamento) se pronuncia favorablemente sobre la designación de fármaco huérfano a una molécula con actividad frente a la Porfíria Eritropoyética Congénita, desarrollada por CIC bioGUNE y ATLAS Molecular Pharma

El Comité para la designación de medicamentos huérfanos (COMP) de la Agencia Europea del Medicamento (EMA) comunica a la compañía vasca Atlas Molecular Pharma S. L. su opinión favorable a la solicitud del fármaco L2.7.D7 [...]

1412, 2017

Atlas Molecular Pharma Receives European Medicines Agency (EMA) Orphan Designation for Congenital Erythropoietic Porphyria

DERIO, Spain.- Atlas Molecular Pharma, a private company founded in 2015 in Derio (Spain) as a spin-off from the Centre for Co-operative Research in Biosciences (CIC bioGUNE), announced today a favourable report, as Orphan Medicinal Product, [...]

1403, 2017

ATLAS Molecular Pharma has been awarded with one of the prestigious NEOTEC grants (2016 call)

ATLAS Molecular Pharma succeeded with the competitive NEOTEC call (CDTI), obtaining a grant for a total amount of 213.000 EUR during the period 2017-2018. The NEOTEC Program aims to support the creation and consolidation of [...]

603, 2017

A possible pharmacological chaperone for congenital erythropoietic porphyria

The Chassys platform has been successfully applied for the identification of a series of putative pharmacological chaperones for the treatment of congenital erythropoietic porphyria. One of them is currently being validated, with most promising results. [...]

1209, 2016

Atlas Molecular Pharma will be attending BioSpain 2016 in Bilbao, September 28th – 30th

Join us at BioSpain 2016 in Bilbao, September 28th – 30th. If you want to find out more about what we do and are a potential Investor or Partner, please contact us through the BioSpain Partnering [...]

Go to Top